Background: Concomitant chemotherapy (CT)-radiotherapy (RT) is a standard of care in locally advanced nasopharyngeal carcinoma (NPC) and a role for induction CT is not established. Results: A total of 83 patients were included in the study. Demographics and tumour characteristics were well balanced between both arms. Most of the patients (95%) in the TPF arm received three cycles of induction CT. The rate of grade 3-4 toxicity and the compliance (NCI-CTCAE v3) during cisplatin-RT were not different between both arms. With a median follow-up of 43.1 months, the 3-year PFS rate was 73.9% in the TPF arm versus 57.2% in the reference arm [hazard ratio (HR) ¼ 0.44; 95% confidence interval (CI): 0.20-0.97, P ¼ 0.042]. Similarly the 3 years overall survival rate was 86.3% in the TPF arm versus 68.9% in the reference arm (HR ¼ 0.40; 95% CI: 0.15-1.04, P ¼ 0.05).
Introduction
Nasopharyngeal carcinomas (NPC) have unique characteristics with a specific geographic distribution (Asia, Mediterranean basin), an association with Epstein-Barr virus and an aggressive locoregional spread along with a high rate of distant metastases [1] .
Radiotherapy (RT) is the cornerstone of initial treatment due to the radiosensitive behaviour of NPC and its deep-seated location. The Meta-Analysis of Chemotherapy (CT) in Nasopharynx Carcinoma (MAC-NPC) [2] based on updated individual patients data showed a survival benefit associated with concomitant CT, but no benefit of either induction or adjuvant CT. The last update of the MAC-NPC confirmed that concomitant RT-CT was the standard of care and showed that induction CT could improve progression-free survival (PFS), distant metastasis and locoregional control rates, without significant survival benefit [3] . In previous randomized studies, some induction CT regimens proved to be highly toxic with up to 8% treatment related deaths [4] , suggesting the need for more optimal regimens. Interestingly the combination of docetaxel-cisplatin-5FU (TPF) has been established as a reference induction treatment in other head and neck cancers (SCC) due to its acceptable tolerance and to its benefit on survival, LRC and distant metastasis, when compared with induction PF [5] [6] [7] [8] . When this trial was initiated, the effect of this reference induction TPF had not been tested in NPC.
Methods

Study design and patients
This was a randomized, multicentre, phase III study (Clinicaltrials.gov: NCT00828386/GORTEC 2006-02), conducted between 2009 and 2012. The study was carried out in accordance with good clinical practice guidelines and was approved by our local ethical committee (Kremlin Bicêtre France).
Eligibility criteria were histological WHO type 2 or 3, stage T2b, T3, T4 and/or N1-N3, M0, PS 0-1 along with haematological, renal, cardiac and liver functions compatible with the use of TPF.
The initial work-up included endoscopy and biopsy, head and neck CT-scanner and/or MRI, bone scintigraphy, liver ultra sound and thoracic CT-scanner.
Treatments
Patients were randomized to receive either RT with concomitant cisplatin 40 mg/m 2 weekly (reference arm) or induction CT with three cycles of TPF followed by RT with concomitant cisplatin 40 mg/m 2 weekly (TPF arm). Each cycle of TPF consisted of docetaxel 75 mg/m 2 day 1; cisplatin 75 mg/m 2 day 1; 5FU 750 mg/m 2 /day days 1-5 every 3 weeks as previously reported [6] . RT consisted of 70 Gy in 2 Gy/fraction, 5 fractions per week with an overall time of 7 weeks.
Randomization
Patients were randomized 1 : 1 to induction TPF followed by concomitant RT-CT or concomitant RT-CT alone with minimization by centre (8 centres) , N stage (N0-1 versus N2-3), and the type of RT (IMRT/non IMRT). To avoid deterministic minimization and assure allocation concealment, the treatment which minimises the imbalance was assigned with a probability of 0.80 (i.e. <1.0). Randomization was carried out at Gustave Roussy.
Statistical analysis
The primary endpoint was PFS, defined as the time from randomization to first progression or death from any cause. Secondary end points were overall survival (OS), loco-regional failure (LRF), distant failure (DF) and acute toxicity according to NCI-CTCAE (version 3) criteria.
Assuming a two-sided type I error of 0.05, observing 89 events (progressions or deaths) out of a total of 260 randomized patients should provide a 85% power to detect a hazard ratio (HR) of 0.53 with the TPF arm when compared with the reference arm (corresponding to a 17% absolute increase of 3 year PFS from 58% to 75%).
Analyses were conducted on 81 patients with since two patients (were lost for follow-up after randomization with no data available). PFS and OS rates were estimated using Kaplan-Meier method. Probabilities of loco-regional progression and metastasis were estimated with 1-KaplanMeier methods, censoring patients without the studied event at the time of last follow-up or death. Rates are presented with Rothman's 95% confidence intervals (CI). Time-to-failure end-points (PFS, OS, LRF, DF) were compared between treatment groups using the log-rank test in univariate analysis and the Cox model to account for minimization factors (country, N stage and the type of RT). All HRs were adjusted for these three parameters. All P-values were two-sided. Median follow-up was estimated with the reverse Kaplan-Meier method.
Results
Study population characteristics
Between 2009 and 2012, 83 patients were enrolled from 8 sites in 2 countries (36 in France and 47 in Tunisia). The trial was closed prematurely due to poor accrual (administrative difficulties were faced in opening Romanian and Morocco centres, as planned). Among the 83 patients 42 and 41 were randomized in the TPF and the reference arm, respectively. In the TPF arm, no data were available for two patients who were lost for follow-up immediately after randomization ( Figure 1 ). Patient demographics and characteristics were well balanced between arms for all the items considered ( Table 1) .
Safety
Compliance and tolerance of induction TPF. In the TPF arm, the number of cycles of TPF received was three cycles in 95% of the patients and 5% received two cycles; 75% of the patients received the full dose of docetaxel, cisplatin and 5FU as planned. No TPF related death was reported. At least one toxicity grade 3 or 4 was seen in 20 patients (50%), especially neutropenia (27.5%), febrile neutropenia (7.5%), mucositis (12.5%), alopecia (15%) and asthenia (10%). Prophylactic Ciprofloxacine was used in 17.5% of patients, whereas primary or secondary uses of G-CSF were reported in 15% and 12.5% of cases, respectively.
Compliance and tolerance to concomitant cisplatin-RT: Two patients randomized in the TPF arm received carboplatin instead of cisplatin during RT-CT. Concomitant cisplatin was given at a higher cumulative dose in the reference arm when compared with the TPF arm ( Table 2 ). Only 13 patients (32.5%) in the TPF arm versus 22 patients (54%) in the reference arm could receive the full dose of concomitant cisplatin as planned. The main reason for not giving the cisplatin as planned was toxicity in both arms. However, the acute toxicity during concomitant RT-CT was not different with 75% of patients with at least one grade 3 or 4 toxicity in the TPF arm and 85% in the reference arm (P ¼ 0.24). Renal and otological toxicities as well as neutropenia and neuropathy were not different between both arms. The rate of severe dysphagia was slightly lower (P ¼ 0.14) in the TPF arm (grade 3-4: 35% versus 51%). Similarly, a feeding tube was necessary only in 8 patients (20%) in the TPF arm when compared with 19 patients (46%) in the reference arm (P ¼ 0.01).
The total dose, dose per fraction and overall time of RT were verified retrospectively by the RT-QA team of the GORTEC. The total dose of RT received and the overall treatment time were not different between both arms with a mean duration of 53.1 days (SD 23.5) in the TPF arm versus 51.8 days (SD 5.4) in the reference arm (P ¼ 0.73). The actual number of fractions received was 35 as planned in most of the patients in both arms (82.5% in the TPF arm versus 90% in the reference arm; P ¼ 0.31). The use of IMRT was declared up-front for each centre and essentially carried out in the French centres (IMRT was not proposed in Tunisia) and not different between both arms (35% in the TPF arm versus 39% in the reference arm).
Efficacy
After induction TPF, a complete response (CR) (Recist) was observed in 7.5% of the patients and a partial response observed in most of them (80%). At 3 months after concomitant CT-RT 80% versus 85% were scored as CR in the TPF and reference arm, respectively.
The median follow-up was 43.1 months, not significantly different between the two arms (42.3 in the TPF arm versus 45.0 in the reference arm). Only four patients were lost to follow-up before 2 years.
PFS events were observed in 28 patients including 14/36 patients in France and 14/45 patients in Tunisia. The first event was death without progression for 3 patients, all in the reference arm (septicaemia, nasopharyngeal bleeding and second malignancy). The 3 year PFS rate was significantly better in the TPF arm than in the reference arm (HR ¼ 0.44; 95% CI: 0.20-0.97; P ¼ 0.042) (Figure 2 ). The HR for PFS was 0.43 among patients treated without IRMT and 0.33 among patients treated with IMRT (interaction test P ¼ 0.79).
The 3 year OS rate was improved in the TPF arm when compared with the reference arm with a HR of 0.40 (95% CI: 0.15-1.04, P ¼ 0.059, Figure 3 ). As shown in Figures 4 and 5 , both the loco-regional control rate and the distant metastases rate were improved in the TPF arm, although the differences did not reach statistical significance. The HR (95% CI) were, respectively, 0.39 (0.13-1.19, P ¼ 0.10) and 0.53 (0.21-1.35, P ¼ 0.18).
Discussion
There is a consensus to consider concomitant CT-RT as the standard of care in locally advanced NPC [1] [2] [3] 9] . However, adding either induction or adjuvant CT might still improve the oncological outcome, as suggested in the recent update of the MAC-NPC meta-analysis [3] . Although induction CT could improve LRC, distant metastases and PFS, its absence of benefit on survival [3] precludes its use in routine practice. However, some induction regimens also proved to be highly toxic [5] , whereas the use of modern induction CT regimens might change treatment options [5] [6] [7] . In this context, the TPF regimen was of particular interest since it became a standard induction regimen for larynx preservation [8] and for other locally advanced HNSCC [5] [6] [7] . Since no randomized data regarding the effect of induction TPF were available in NPC the aim of our study was to evaluate its potential added value. The strengths of our trial were related to its rigorous methodology, auditing 100% of the data and the fact that this was a first attempt to evaluate in a randomized trial the 'reference TPF' regimen before CT-RT in locally advanced NPC. On the contrary, a major weakness of this trial is the early discontinuation leading to a lack of statistical power and potential risks of false positive/negative findings. The decision to stop the trial was taken after the withdrawal of Morocco and Romania centres and since the projection for accruing 260 patients as planned was 12-13 years with such an accrual rate. Another potential limitation of our study is the under usage of IMRT, which is considered now as a standard of care in locally advanced NPC [1] . However, most of the data generated from previous randomized trials and included so far in the MAC-NPC data base also did not use IMRT [2, 3, 10, [11] [12] [13] . In addition, in our study, there was no interaction between the induction TPF and the use of IMRT on PFS and OS. Progression free survival Figure 2 . Probability of progression-free survival HR and P value were calculated after adjustment for country, node stage and radiotherapy type. . Probability of loco-regional progression HR and P value were calculated after adjustment for country, node stage and radiotherapy type.
Despite of the limited number of patients, important conclusions can be drawn regarding tolerance, compliance and toxicity, which were better than expected from previous studies carried out in other HNC. Indeed, tolerance and compliance to induction TPF were good (95% of the patients received three cycles), as well as for the concomitant phase with significant but relatively small differences in the total cumulative dose of cisplatin received and relatively good tolerance of concomitant cisplatin in the TPF arm. The good tolerance of TPF could be related to the fact that patients with NPC were younger (on average 10 years) and had less comorbidities compared with HNSCC patients for whom the TPF regimen was previously tested [6, 7] . Interestingly, our results are in good agreement with the results of a small randomized trial which tested induction docetaxel and cisplatin both at 75 mg/m 2 for two cycles before concomitant cisplatin-RT, and strongly suggesting that cisplatin-docetaxel-based induction treatment could be of benefit for patients with locally advanced NPC [10] whereas such a trend has not been observed in some randomized trials having used alternative induction regimen [11] [12] [13] . More importantly, a large scale randomized trial has been reported recently [14] testing induction TPF before concomitant CT-RT versus concomitant CT-RT with a comparable design [14] except that the dose intensity of TPF was lower (60 mg/m 2 for both cisplatin and docetaxel and 600 mg/m 2 of 5FU). Interestingly comparable outcomes were reported in this trial, showing also acceptable toxicity along with a significant improvement in failure-free survival [14] . Taken together, the results of these two randomized trials urge to perform confirmatory trials to evaluate whether this TPF combinatory strategy could become a new standard of care for locally advanced NPC. The results of our trial are also in agreement with our recent network meta-analysis strongly suggesting that adding CT either induction or adjuvant could improve the outcome when compared with RT-CT alone [15] . A more recent phase III trial showed that induction PF could also improve tumour control compared with CT-RT alone in loco-regionally advanced NPC, particularly at distant sites, although there was no early gain in overall survival [16] . Overall these large-scale phase III trials [14, 16] along with our results and with those of the recent up-date of the MAC-NPC meta-analysis [5] suggest a potential role of induction CT before concomitant RT-CT in locally advanced NPC, perhaps important to consider for the patients with bulky neck nodes or heavy tumour burden.
In conclusion, the compliance to induction TPF was good and its use associated only with slight reduction of cisplatin dose administered concomitantly with RT. The improvement in PFS and OS is in agreement with a recent induction TPF trial [14] and strongly suggest a need for further confirmatory trial. Figure 5 . Probability of distant metastasis HR and P value were calculated after adjustment for country, node stage and radiotherapy type.
